Lauren Floyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren Floyd has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Ajay Dhaygude
Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital Department of Nephrology
11 shared publicationsAdam D Morris
Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital Department of Nephrology
5 shared publications- Adam D. Morris
Renal Medicine, Royal Preston Hospital, Preston, United Kingdom
5 shared publications - Alexander Woywodt
Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital Department of Nephrology
4 shared publications - Henry H. L. Wu
Donal O’Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK
4 shared publications Madelena Stauss
Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust , Preston, Lancashire , UK
4 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Avacopan: Is it the end of the road?
- 30 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Open AccessAvacopan: Is it the end of the road?
- Open Access
- 30 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Redefining Renal Remission in ANCA-Associated Vasculitis: A Contemporary Review and Proposal for New Criteria
Kidneys are among the major organs affected in Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and achieving renal remission remains a central goal of disease management. Accurate distinction between active disease and remission is essential for guiding immunosuppressive therapy. However, a universally accepted definition of remission is still lacking, and the ability to reliably measure it remains challenging. Traditional markers, including ANCA titres and proteinuria, have notable limitations in reflecting true disease activity. This review examines how disease activity and remission have been defined in the literature and clinical trials, and evaluates the strengths and limitations of currently available traditional, serological, and novel biomarkers, alongside histological confirmation. Drawing on existing evidence, we propose a candidate set of criteria for defining renal remission in AAV, intended to inform future consensus-driven validation rather than for immediate clinical use, and highlight the urgent need for such validation studies.
- 30 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
Open AccessRedefining Renal Remission in ANCA-Associated Vasculitis: A Contemporary Review and Proposal for New Criteria
Kidneys are among the major organs affected in Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and achieving renal remission remains a central goal of disease management. Accurate distinction between active disease and remission is essential for guiding immunosuppressive therapy. However, a universally accepted definition of remission is still lacking, and the ability to reliably measure it remains challenging. Traditional markers, including ANCA titres and proteinuria, have notable limitations in reflecting true disease activity. This review examines how disease activity and remission have been defined in the literature and clinical trials, and evaluates the strengths and limitations of currently available traditional, serological, and novel biomarkers, alongside histological confirmation. Drawing on existing evidence, we propose a candidate set of criteria for defining renal remission in AAV, intended to inform future consensus-driven validation rather than for immediate clinical use, and highlight the urgent need for such validation studies.
- Open Access
- 1 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (10)
A critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis
Objectives: We aimed to appraise 11 currently available guidelines for ANCA-associated vasculitis (AAV), identify potential gaps, and provide recommendations for improvement. Methods: The guidelines were appraised using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument consisting of 23 appraisal criteria/items across six domains (D). Four reviewers independently appraised guidelines and scaled domain scores were calculated. Results: The average score of all guidelines was 4.5 ± 0.8 out of 7.0. Agreement between the reviewers was excellent. British Society for Rheumatology 2025 guidelines scored highest (5.8/7.0), being the only guideline unanimously recommended for use. In ‘D1/Scope and purpose’, all guidelines achieved high scores. In ‘D2/Stakeholder involvement’, major gaps were identified in the inclusion of the views and preferences of the target population (2c), with few guidelines including patient representatives, addressing patient participation, or considering patient views. In ‘D3/Rigour of development’, all but two guidelines received high scores. Implementation of the procedure for updating the guidelines (3 h) and for external review (3 g) was addressed poorly. In ‘D4/Clarity of presentation’, all guidelines except one received a high score. ‘D5/Applicability’ had the lowest scores due to gaps in the criteria for monitoring/auditing guideline implementation (5d), resource/cost implications (5c), lack of advice/tools for implementation (5a), and inadequate addressing of facilitators/barriers in guideline application (5a). ‘D6/Editorial independence’ was addressed well. Conclusions: Several aspects of AAV guidelines could be improved, including the inclusion of patient views and preferences, the processes for translating guidelines into clinical practice, and clearer criteria for monitoring guideline implementation and uptake.
- 1 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (10)
Open AccessA critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis
Objectives: We aimed to appraise 11 currently available guidelines for ANCA-associated vasculitis (AAV), identify potential gaps, and provide recommendations for improvement. Methods: The guidelines were appraised using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument consisting of 23 appraisal criteria/items across six domains (D). Four reviewers independently appraised guidelines and scaled domain scores were calculated. Results: The average score of all guidelines was 4.5 ± 0.8 out of 7.0. Agreement between the reviewers was excellent. British Society for Rheumatology 2025 guidelines scored highest (5.8/7.0), being the only guideline unanimously recommended for use. In ‘D1/Scope and purpose’, all guidelines achieved high scores. In ‘D2/Stakeholder involvement’, major gaps were identified in the inclusion of the views and preferences of the target population (2c), with few guidelines including patient representatives, addressing patient participation, or considering patient views. In ‘D3/Rigour of development’, all but two guidelines received high scores. Implementation of the procedure for updating the guidelines (3 h) and for external review (3 g) was addressed poorly. In ‘D4/Clarity of presentation’, all guidelines except one received a high score. ‘D5/Applicability’ had the lowest scores due to gaps in the criteria for monitoring/auditing guideline implementation (5d), resource/cost implications (5c), lack of advice/tools for implementation (5a), and inadequate addressing of facilitators/barriers in guideline application (5a). ‘D6/Editorial independence’ was addressed well. Conclusions: Several aspects of AAV guidelines could be improved, including the inclusion of patient views and preferences, the processes for translating guidelines into clinical practice, and clearer criteria for monitoring guideline implementation and uptake.
- 6 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Comment on: A systematic review of patient-reported outcome measures in patients with ANCA-associated vasculitis: reply
- 6 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Comment on: A systematic review of patient-reported outcome measures in patients with ANCA-associated vasculitis: reply
- Open Access
- 16 February 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Pillar or poison? Evaluating overdose and safety challenges in newer diabetic kidney disease medications
- 16 February 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (4)
Open AccessPillar or poison? Evaluating overdose and safety challenges in newer diabetic kidney disease medications
- 21 May 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (11) , 1623-1625
The Florence Working Group
An abstract is unavailable. This article is available as a PDF only.
- 21 May 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (11) , 1623-1625
The Florence Working Group
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 25 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (6) , 2074-2075
Response to the Letter to the Editor Entitled “Focusing on Older Adults With Antineutrophil Cytoplasmic Autoantibody Negative Pauci-Immune Glomerulonephritis”
- 25 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (6) , 2074-2075
Open AccessResponse to the Letter to the Editor Entitled “Focusing on Older Adults With Antineutrophil Cytoplasmic Autoantibody Negative Pauci-Immune Glomerulonephritis”
- Open Access
- 3 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1450-1459
Clinical Presentation and Outcomes of Antineutrophil Cytoplasmic Autoantibody–Negative Pauci-Immune Glomerulonephritis
- 3 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1450-1459
Open AccessClinical Presentation and Outcomes of Antineutrophil Cytoplasmic Autoantibody–Negative Pauci-Immune Glomerulonephritis
- Open Access
- 20 June 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (7) , sfae170
To the lighthouse: navigating nephrology through the world of social media
Back in 2009, two articles in NDT Plus, the predecessor of CKJ, described opportunities for using the internet [ 1, 2]. A decade and a half later, this practice has gone viral. We live and work in an ever-expanding ‘socialverse’, with >5 billion people globally using social media (SoMe) platforms, partly as professional and educational tools. However, adoption remains low in some low- and middle-income countries (LMICs) [ 3], with some studies suggesting that higher tweet numbers can be a proxy for gross domestic product (GDP) [ 4]. Risks also exist and regulations range from non-existent to minutely prescriptive, with serious sanctions if guidance is breached [ 5]. So, in an age of instant information, with a multiverse of options available at a single touch, how best to navigate through this world of opportunity and risk? Here, we provide a brief primer on SoMe in nephrology, focusing on advantages, pitfalls and tips for maximizing utility for clinicians. Finally, we highlight a list of challenges for the next decade, which will undoubtedly take us on a journey to an entirely new realm of connectivity.
- 20 June 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (7) , sfae170
Open AccessTo the lighthouse: navigating nephrology through the world of social media
Back in 2009, two articles in NDT Plus, the predecessor of CKJ, described opportunities for using the internet [ 1, 2]. A decade and a half later, this practice has gone viral. We live and work in an ever-expanding ‘socialverse’, with >5 billion people globally using social media (SoMe) platforms, partly as professional and educational tools. However, adoption remains low in some low- and middle-income countries (LMICs) [ 3], with some studies suggesting that higher tweet numbers can be a proxy for gross domestic product (GDP) [ 4]. Risks also exist and regulations range from non-existent to minutely prescriptive, with serious sanctions if guidance is breached [ 5]. So, in an age of instant information, with a multiverse of options available at a single touch, how best to navigate through this world of opportunity and risk? Here, we provide a brief primer on SoMe in nephrology, focusing on advantages, pitfalls and tips for maximizing utility for clinicians. Finally, we highlight a list of challenges for the next decade, which will undoubtedly take us on a journey to an entirely new realm of connectivity.
- Open Access
- 7 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0298796
Developing a disease-specific patient reported outcome measure to enhance understanding of the lived experiences of ANCA associated vasculitis: A protocol paper
Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a chronic, relapsing-remitting condition associated with increased morbidity. Previous research has shown patients with AAV report high levels of fatigue, pain, depression and anxiety. Over recent years successful work has been carried out to improve clinical outcomes, resulting in reduced mortality and end stage kidney disease (ESKD). Despite this, little work has been done to better understand the role of the patient within this condition. The prevalence of AAV is increasing and to date, there is a shortage of specific tools that assess and measure key features relating to patient reported outcomes (PROs). This protocol details how we can better understand the lived experiences of those with AAV through the development of a disease specific, patient reported outcome measure (PROM), to be used in clinic practice. This will allow us to recognise and validate PROs and the impact the disease and its treatment has on patients’ health related quality of life (HRQoL). In addition, we aim to identify potential differences in PRO’s between demographics, organ involvement and treatment subgroups in AAV as well as outcomes relating to the patient experience. Patients from a single centre in the UK will be recruited to take part in the exploratory qualitative study which will include focus groups and semi-structured interviews. The inclusion criteria comprise anyone with a diagnosis of AAV and willing to participate, including those who have active or relapsing disease, those are economically active, unemployed, retired and patients receiving renal replacement therapy. The aim of the project is to identify key issues patients experience in relation to their disease and its management and how these can be better assessed in a new PROM developed for use in the clinic setting. This will enable better delivery of individualised care and inform shared decision making, while also serving as a platform for future research looking at PROs in other glomerulonephritides.
- 7 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0298796
Open AccessDeveloping a disease-specific patient reported outcome measure to enhance understanding of the lived experiences of ANCA associated vasculitis: A protocol paper
Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a chronic, relapsing-remitting condition associated with increased morbidity. Previous research has shown patients with AAV report high levels of fatigue, pain, depression and anxiety. Over recent years successful work has been carried out to improve clinical outcomes, resulting in reduced mortality and end stage kidney disease (ESKD). Despite this, little work has been done to better understand the role of the patient within this condition. The prevalence of AAV is increasing and to date, there is a shortage of specific tools that assess and measure key features relating to patient reported outcomes (PROs). This protocol details how we can better understand the lived experiences of those with AAV through the development of a disease specific, patient reported outcome measure (PROM), to be used in clinic practice. This will allow us to recognise and validate PROs and the impact the disease and its treatment has on patients’ health related quality of life (HRQoL). In addition, we aim to identify potential differences in PRO’s between demographics, organ involvement and treatment subgroups in AAV as well as outcomes relating to the patient experience. Patients from a single centre in the UK will be recruited to take part in the exploratory qualitative study which will include focus groups and semi-structured interviews. The inclusion criteria comprise anyone with a diagnosis of AAV and willing to participate, including those who have active or relapsing disease, those are economically active, unemployed, retired and patients receiving renal replacement therapy. The aim of the project is to identify key issues patients experience in relation to their disease and its management and how these can be better assessed in a new PROM developed for use in the clinic setting. This will enable better delivery of individualised care and inform shared decision making, while also serving as a platform for future research looking at PROs in other glomerulonephritides.